PDGFR

<p>Imatinib Mesylate (STI-571) is a tyrosine kinase receptor inhibitor with antineoplastic activity (IC50s: 0.6 μM, 0.1 μM and 0.1 μM for v-Abl, c-Kit and PDGFR,</p>

<p>Sunitinib Malate (Sunitinib) is an indolinone-based tyrosine kinase inhibitor.</p>

<p>N-Desmethyl imatinib (Imatinib metabolite N-Desmethyl imatinib) is a metabolite of Imatinib, which is a multi-target inhibitor of c-Kit, v-Abl, and PDGFR.</p>

<p>Trapidil (Avantrin) is a coronary vasodilator agent.</p>

<p>Axitinib (AG-013736) is a multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1/2/3 and PDGFRβ. Axitinib has antitumor activity. Cost-effective and quality-assured.</p>

<p>Pazopanib (GW786034) is an inhibitor of protein tyrosine kinases that inhibits VEGFR1/2/3. Pazopanib has antitumor activity. Cost-effective and quality-assured.</p>

<p>Olaratumab(IMC-3G3) is a human monoclonal IgG1 antibody against platelet-derived growth factor receptor alpha (PDGFRα), which has antitumor effects and can be</p>

<p>JNJ-10198409: selective ATP competitive PDGF-RTK inhibitor; IC50: PDGFR-β 4.2 nM, PDGFR-α 45 nM; antiangiogenic &amp; antiproliferative.</p>

<p>Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase (RTK) inhibitor that inhibits VEGFR2 and PDGFRβ (IC50=80/2 nM).</p>

<p>Lenvatinib (E7080) is a multi-target receptor tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, KIT, PDGFR, and RET, and has oral activity.</p>

<p>AG 1295 is a selective PDGFR tyrosine-kinase inhibitor; it blocks PDGFR autophosphorylation without affecting EGF receptor.</p>

<p>Regorafénib N-oxyde M2 is an active metabolite of Regorafenib.</p>

<p>KN1022 is an inhibitor of phosphorylation of platelet-derived growth factor (PDGF) receptor with IC50 of 0.26 μM.</p>

<p>CT52923: selective oral PDGFR blocker, ATP-inhibitor, used in research for various diseases including cancer.</p>

<p>KIT/PDGFRA-IN-1 (compound 19) is an inhibitor targeting the stem cell growth factor receptor (KIT) and platelet-derived growth factor receptor alpha (PDGFRA). Its IC50 values are 2.3 µM for KIT-wt, 12 µM for KIT-D816H, 492 µM for KIT-T670I, 0.8 µM for PDGFRA-wt, 99.9 µM for PDGFRA-D842V, 42.3 µM for PDGFRA-T674I, and 4.3 µM for PDGFRA-G680R. The GR50 values for GIST-T1, T1-a-D842V, and GIST-48B cell lines (gastrointestinal stromal tumor cell lines with PDGFR and KIT mutations) are 12 nM, 8900 nM, and ≥10,000 nM, respectively.</p>

<p>KG5 inhibits PDGFRβ, B-Raf, FLT3, KIT, c-Raf; has anticancer and antiangiogenic effects; Kd: 520 nM (PDGFRβ), 300 nM (PDGFRα).</p>

<p>IMC-2C5 is a humanized monoclonal antibody targeting PDGFRB/CD140b.</p>

<p>A unique collection of 1016 tyrosine kinase inhibitors for high throughput screening and high content screening for drug discovery in tyrosine kinase related</p>

<p>Rinucumab (REGN 2176) is an anti-PDGF IgG4-like monoclonal antibody that can be used to study age-related macular degeneration.</p>

<p>Anti-PDGFRB Antibody-APC (1A610) is a APC-conjugated Mouse antibody targeting PDGFRB. Anti-PDGFRB Antibody-APC (1A610) can be used in FCM.</p>

<p>Anti-Phospho-PDGFRB (Tyr740) Antibody (9D509) is an antibody targeting Phospho-PDGFRB (Tyr740). Anti-Phospho-PDGFRB (Tyr740) Antibody (9D509) can be used in ELISA, WB.</p>

<p>Anti-PDGFRB Antibody (7C914) is a Rabbit antibody targeting PDGFRB. Anti-PDGFRB Antibody (7C914) can be used in FCM.</p>

<p>Anti-PDGFRB Antibody (4V910) is a Rabbit antibody targeting PDGFRB. Anti-PDGFRB Antibody (4V910) can be used in ELISA.</p>

<p>Anti-PDGFRB Antibody-FITC (1A610) is a FITC-conjugated Mouse antibody targeting PDGFRB. Anti-PDGFRB Antibody-FITC (1A610) can be used in FCM.</p>

<p>Anti-PDGFRB Antibody (7W816) is a Mouse antibody targeting PDGFRB. Anti-PDGFRB Antibody (7W816) can be used in ELISA(Cap).</p>

<p>Anti-PDGFRB Antibody-FITC (7C914) is a FITC-conjugated Rabbit antibody targeting PDGFRB. Anti-PDGFRB Antibody-FITC (7C914) can be used in FCM.</p>

<p>Anti-PDGFRB Antibody (1A610) is a Mouse antibody targeting PDGFRB. Anti-PDGFRB Antibody (1A610) can be used in ELISA,FCM.</p>

<p>Anti-PDGFRB Antibody-APC (7C914) is a APC-conjugated Rabbit antibody targeting PDGFRB. Anti-PDGFRB Antibody-APC (7C914) can be used in FCM.</p>

<p>Anti-PDGFRB Antibody (8J167) is an antibody targeting PDGFRB. Anti-PDGFRB Antibody (8J167) can be used in ELISA, IHC.</p>

<p>Anti-PDGFRB Antibody-PE (1A610) is a PE-conjugated Mouse antibody targeting PDGFRB. Anti-PDGFRB Antibody-PE (1A610) can be used in FCM.</p>

<p>Anti-PDGFRB Antibody-PE (7C914) is a PE-conjugated Rabbit antibody targeting PDGFRB. Anti-PDGFRB Antibody-PE (7C914) can be used in FCM.</p>

<p>Anti-PDGFRB Antibody (4H405) is a Mouse antibody targeting PDGFRB. Anti-PDGFRB Antibody (4H405) can be used in ELISA(Det).</p>

<p>PDGF R beta/CD140b Protein, Human, Recombinant (His &amp; Avi) is expressed in HEK293 mammalian cells with C-His-Avi tag.</p>

<p>PDGFRB Protein, Human, Recombinant (His), Biotinylated is expressed in HEK293 mammalian cells with His tag.</p>

<p>PDGF R beta/CD140b Protein, Human, Recombinant (His &amp; Avi), Biotinylated is expressed in HEK293 mammalian cells with C-His-Avi tag.</p>

<p>PDGF R beta/CD140b Protein, Canine, Recombinant (His) is expressed in HEK293 mammalian cells with C-His tag.</p>

<p>PDGFRB Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag.</p>

<p>PDGFRB Protein, Human, Recombinant is expressed in HEK293 mammalian cells. The predicted molecular weight is 56.2 kDa and the accession number is P09619-1.</p>

<p>PDGFRB Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag.</p>

<p>PD-161570 is a potent and ATP-competitive human FGF-1 receptor inhibitor with an IC50 of 39.9 nM and a Ki of 42 nM.</p>

<p>SU-4312 (DMBI) inhibits VEGFR &amp; PDGFR (IC50: 0.8, 19.4 μM) and shields neurons from MPP(+)-induced damage by blocking nNOS.</p>

<p>PP-121 inhibits PDGFR, Hck, mTOR, VEGFR2, Src, Abl, and DNA-PK with IC50 values ranging from 2 to 60 nM.</p>

<p>Masitinib mesylate (AB-1010 mesylate) is a selective and orally bioavailable c-Kit inhibitor (IC50 of 200 nM,540/800 nM,510 nM for human recombinant c-Kit;</p>

<p>TAK-593 is an effective VEGFR and PDGFR family inhibitor (IC50s: 3.2, 0.95, 1.1, 4.3, and 13 nM for VEGFR1, VEGFR2, VEGFR3, PDFGRα, and PDFGRβ, respectively).</p>

<p>Seralutinib (GB002) is an inhibitor of inhaled PDGFRα and PDGFRβ. It is used in the study for pulmonary arterial hypertension.</p>

<p>Amuvatinib (MP470) is an orally bioavailable synthetic carbothioamide with potential antineoplastic activity.</p>

<p>PD 089828 inhibits FGFR1, PDGFRβ, EGFR (IC50s: 0.15-5.47 μM), and c-Src (IC50: 0.18 μM).</p>

<p>Crenolanib (ARO 002) is an orally bioavailable type III tyrosine kinases inhibitor of PDGFRα/β and FLT3 (IC50s: 11, 3.2, and 4 nM).</p>

<p>Vorolanib (X-82) is an orally active VEGFR/PDGFR dual inhibitor.</p>

<p>Masitinib (AB1010) is a tyrosine-kinase inhibitor used in the treatment of mast cell tumors in animals, specifically dogs.</p>

<p>Avapritinib (BLU-285) is a selective, highly potent, and orally active inhibitor of KIT and PDGFRA activation loop mutant kinases.Cost-effective and quality-assured.</p>

<p>Nintedanib esylate (BIBF 1120 esylate) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β</p>

<p>Multi-kinase inhibitor 1 (Multi-kinase inhibitor I) is a Multi-kinase inhibitor.</p>

<p>Ki-20227 is a specific c-Fms tyrosine kinase(CSF1R) inhibitor (IC50: 2 nM).</p>

<p>Toceranib Phosphate (SU11654 phosphate), is a selective inhibitor of the tyrosine kinase activity of several members of the split kinase RTK family.</p>

<p>Flumatinib (HHGV678) is an orally bioavailable tyrosine kinase inhibitor flumatinib, with potential antineoplastic activity.</p>

<p>Tyrphostin A9 (SF 6847) is an Agricultural acaricide, now superseded. Tyrphostin A9 is firstly designed as an EGFR inhibitor</p>

<p>N-(p-Coumaroyl) Serotonin, from safflower seeds, has antioxidant, antitumor properties and improves vascular health.</p>

<p>SU 5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC50 of 20 nM, 30 nM, and 510 nM for VEGFR2, FGFR1, and PDGF-Rβ, respectively.</p>

<p>AZD2932 is a potent and multi-targeted kinase inhibitor VEGFR2, PDGFβ, Flt-3, and c-Kit.</p>

<p>Sennoside B is an anthranoid. Anthranoid derivatives are used all over the world as a treatment for constipation.</p>

<p>Dovitinib lactate hydrate (TKI258) is the Lactate of Dovitinib, which is a multitargeted RTK inhibitor, mostly for class III (FLT3/c-Kit).</p>

<p>Dovitinib lactate (TKI-258 lactate)(TKI258) lactate is a potent inhibitor of fibroblast growth factor receptor 3 (FGFR3) (IC50 :5 nM).</p>

<p>Cediranib (AZD2171) is a potent KDR tyrosine kinase inhibitor (IC50 &lt; 1nM), also targets Flt1/4, PDGFRβ, c-Kit, and more selective for VEGFR.</p>

<p>Tandutinib (CT53518) (MLN518, CT53518), an effective FLT3 antagonist (IC50: 0.22 μM), can also inhibit c-Kit and PDGFR, 15-20 fold higher potency for FLT3</p>

<p>ON123300 is a potent and multi-targeted kinase inhibitor for CDK4/Ark5/PDGFRβ/FGFR1/RET/Fyn (IC50: 3.9/5/26/26/9.2/11 nM).</p>

<p>Orantinib (NSC 702827) , a excellent effective against PDGFR autophosphorylation with Ki of 8 nM, also highly inhibits Flk-1 and FGFR1 trans-phosphorylation.</p>

<p>Tyrphostin AG1296 (Tyrphostin AG 1296) is an inhibitor of PDGFR with IC50 of 0.3-0.5 μM, no activity to EGFR.</p>

<p>SU4984 is a cell-permeable, ATP-competitive and reversible inhibitor of the fibroblast growth factor receptor 1 (FGFR1).</p>

<p>JI-101 (CGI-1842) is an oral multi-kinase inhibitor that targets VEGFR-2, PDGFR-β, and EphB4.</p>

<p>Ilorasertib (ABT-348) inhibits Aurora kinases A/B/C &amp; RET, PDGFRβ, Flt1 (IC50: 1-120 nM).</p>

<p>Imatinib (STI571) is a multi-targeted receptor tyrosine kinase inhibitor that selectively inhibits the kinase activities of BCR/ABL, v-Abl, PDGFR, and c-kit</p>

<p>Telatinib (Bay 57-9352) inhibits VEGFR2/3, c-Kit, PDGFRα with IC50s: 6 nM, 4 nM, 1 nM, 15 nM.</p>

<p>Methylnissolin (3-Hydroxy-9,10-dimethoxyptercarpan) is derived from Astragalus and has antibacterial and anti-cancer effects.</p>

<p>Regorafenib Monohydrate is a novel oral multikinase inhibitor with IC50 values of 13, 4.2, 46, 22, 7, 1.5, 2.5, 28, 19 nM for VEGFR1, murine VEGFR2, murine</p>

<p>Lenvatinib mesylate (E7080 (mesylate)) is an oral and multi-targeted inhibitor of VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, with potent antitumor activities.</p>

<p>Linifanib (AL-39324) (ABT-869) is a novel, potent ATP-competitive VEGFR/PDGFR inhibitor for KDR (IC50: 4 nM), CSF-1R (IC50: 3 nM), Flt-1/3 (IC50: 3/4 nM) and</p>

<p>PD168393 is an irreversible EGFR inhibitor (IC50: 0.70 nM), irreversibly alkylate Cys-773; inactive against PKC, FGFR, PDGFR, and insulin.</p>

<p>Pazopanib HCl (Votrient) inhibits VEGFR1-3, PDGFR, FGFR, c-Kit, c-Fms with IC50 range 10-146 nM in cell-free assays.</p>

<p>CHIR-124 is an effective Chk1 inhibitor (IC50: 0.3 nM). It has 2, 000-fold selectivity against Chk2, 500- to 5, 000-fold less activity against Cdc2 and CDK2/4.</p>

<p>Ponatinib (AP24534) is an orally available, multitargeted kinase inhibitor (IC50s: 0.37/1.1/1.5/2.2/5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively</p>

<p>Regorafenib (BAY 73-4506) is a multi-targeted receptor tyrosine kinase inhibitor that inhibits RET, C-RAF, VEGFR2, c-Kit, VEGFR1, and PDGFRβ and is orally</p>

<p>Ripretinib (DCC-2618) is an orally bioavailable inhibitor of KIT and PDGFRA.</p>